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“CHRI”sis in the NICU: The Medley with Midazolam

Introduction

Reeyan Bhakat1,3, Nghi M. Nguyen1, Victoria Schaal1 and Gurudutt Pendyala1,3*
1Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE;
2Children’s Hospital & Medical Center, Omaha, NE
3Child Health Research Institute, Omaha, NE
Contact: gpendyala@unmc.edu
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Results

Approximately 1.5 million neonates undergo anesthesia for surgical procedures in the
United States every year1. Notably, Midazolam, a commonly used anesthetic agent is
used in the Neonatal Intensive Care Unit (NICU) to sedate neonates and facilitate complex
procedures such as mechanical ventilation.2 One knowledge gap pertaining the use of
midazolam is its ability to affect cognitive development of infants. In 2014, the International
Anesthesia Research Society released a statement saying, “Surgeries and procedures
requiring anesthetic and sedative drugs that could reasonably be delayed should possibly
be postponed because of the potential risk to the developing brain of infants, toddlers, and
preschool children”. 3 Although some evidence has shown midazolam exposure could
harm an infant’s cognitive development, little is known about the molecular and behavioral
underpinnings and if these changes persist into adulthood. In our current study employing
a preclinical animal model system, we for the first time present a comprehensive
characterization on how early life exposure to midazolam impacts neurodevelopment
outcomes at different tiers ─ phenotypic, molecular and behavioral levels and if these
changes persist during early adulthood.
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Figure 1. Phenotypic measurements at various time points: At P7 (7 days after birth), there was a significant difference in the body weight, head size circumference, and body length
between the saline and midazolam groups. At P14 and P21, there was only a significant difference in body weight between the saline and midazolam groups. These results suggest that
physical growth is stunted at childhood but not adulthood. *p <0.05, ** p< 0.01; ****p< 0.0001 as determined by Two-Way ANOVA followed by a post-hoc Sidak’s test. Each bar represents the
mean + SEM.

Central Hypothesis
Long term exposure to midazolam at early stages of life
can potentially perturb neurodevelopmental outcomes
that could further persist into adulthood.
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Figure 4. Behavioral tests
(Social novelty): Throughout the
course of 15 minutes, the number
of seconds, contacts, and
chamber entries that the rat
allocated between the naïve and
cage mate rat were recorded.
Midazolam-exposed rats had
fewer entries to both naïve and
cagemate chamber, in
comparison to the controls. For
contacts, the P28 and P60
Midazolam rats at more contacts
for both the naïve and cage mate
rat. However, at P45, the
Midazolam group had less
contacts for both naïve and cage
mate as compared to the Saline
group. For time spent, the
Midazolam group only had a
longer duration as compared to
the Saline group in P45 for the
naïve rat and at P60 for the cage
mate rat. Two-Way ANOVA
followed by a post-hoc Sidak’s
test revealed no significant
differences (n=14-18/group).
Each bar represents the mean +
SEM.

Methods & Design
Conclusion and Future Directions

Figure 2. Expression of Blood brain barrier proteins: At P21, the level of albumin, and connexin is slightly downregulated in midazolam-exposed brains, while JAM-1, Occludin, and ZO-1 levels are
slightly upregulated. At P60, there is no difference in level of expression of albumin and JAM-1 between saline and midazolam group; however, the level of Connexin, Occludin, and ZO-1 are slightly
decreased in midazolam-exposed brains. This suggests that Midazolam potentially alternate the regulation in key blood brain barrier proteins. Two-Way ANOVA followed by a post-hoc Sidak’s test
revealed no significant differences (n=12/group). Each bar represents the mean + SEM.
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Purified Synaptosomes

• From these results on the phenotypic, molecular, and behavioral level, it can be
established that Midazolam could potentially stunt neurodevelopment during
early stages of life/
• Midazolam-exposed rats display significant phenotypic alterations in their
earlier stages of life.
• Midazolam exposure has subtle effects on expression of blood brain barrier and
synaptic protein levels.
• On the behavioral level, the preference of the midazolam-exposed rats to its
cage mate (higher number of contacts) and unwillingness to explore (lower
number of entries) can implicate a social deficit.
• Do subtle changes in BBB and synaptic proteins impact synaptic currents (cf.
spine density, neurotransmitter release dynamics etc.)?
• Are levels of growth factors impaired in the midazolam exposed animals?
• Increasing the sample size to determine potential sex-specific differences
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